393 related articles for article (PubMed ID: 29127322)
1. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
[TBL] [Abstract][Full Text] [Related]
2. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
[TBL] [Abstract][Full Text] [Related]
5. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus.
Yan H; Li W
Dig Dis; 2015; 33(3):388-96. PubMed ID: 26045274
[TBL] [Abstract][Full Text] [Related]
6. Selective hepatitis B and D virus entry inhibitors from the group of pentacyclic lupane-type betulin-derived triterpenoids.
Kirstgen M; Lowjaga KAAT; Müller SF; Goldmann N; Lehmann F; Alakurtti S; Yli-Kauhaluoma J; Glebe D; Geyer J
Sci Rep; 2020 Dec; 10(1):21772. PubMed ID: 33303817
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors.
Kirstgen M; Lowjaga KAAT; Müller SF; Goldmann N; Lehmann F; Glebe D; Baringhaus KH; Geyer J
Viruses; 2021 Apr; 13(4):. PubMed ID: 33921515
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
Shimura S; Watashi K; Fukano K; Peel M; Sluder A; Kawai F; Iwamoto M; Tsukuda S; Takeuchi JS; Miyake T; Sugiyama M; Ogasawara Y; Park SY; Tanaka Y; Kusuhara H; Mizokami M; Sureau C; Wakita T
J Hepatol; 2017 Apr; 66(4):685-692. PubMed ID: 27890789
[TBL] [Abstract][Full Text] [Related]
9. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
[TBL] [Abstract][Full Text] [Related]
10. Long-term
Lowjaga KAAT; Kirstgen M; Müller SF; Goldmann N; Lehmann F; Glebe D; Geyer J
Am J Physiol Gastrointest Liver Physiol; 2021 Jan; 320(1):G66-G80. PubMed ID: 33174454
[TBL] [Abstract][Full Text] [Related]
11. Interactions of Na
Zakrzewicz D; Geyer J
Biol Chem; 2023 Jun; 404(7):673-690. PubMed ID: 37103224
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel HBV/HDV Entry Inhibitors by Pharmacophore- and QSAR-Guided Virtual Screening.
Kirstgen M; Müller SF; Lowjaga KAAT; Goldmann N; Lehmann F; Alakurtti S; Yli-Kauhaluoma J; Baringhaus KH; Krieg R; Glebe D; Geyer J
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452354
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide.
Yan H; Peng B; He W; Zhong G; Qi Y; Ren B; Gao Z; Jing Z; Song M; Xu G; Sui J; Li W
J Virol; 2013 Jul; 87(14):7977-91. PubMed ID: 23678176
[TBL] [Abstract][Full Text] [Related]
14. Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout mice.
Slijepcevic D; Kaufman C; Wichers CG; Gilglioni EH; Lempp FA; Duijst S; de Waart DR; Elferink RP; Mier W; Stieger B; Beuers U; Urban S; van de Graaf SF
Hepatology; 2015 Jul; 62(1):207-19. PubMed ID: 25641256
[TBL] [Abstract][Full Text] [Related]
15. IFITM3 Interacts with the HBV/HDV Receptor NTCP and Modulates Virus Entry and Infection.
Palatini M; Müller SF; Kirstgen M; Leiting S; Lehmann F; Soppa L; Goldmann N; Müller C; Lowjaga KAAT; Alber J; Ciarimboli G; Ziebuhr J; Glebe D; Geyer J
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458456
[TBL] [Abstract][Full Text] [Related]
16. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).
Veloso Alves Pereira I; Buchmann B; Sandmann L; Sprinzl K; Schlaphoff V; Döhner K; Vondran F; Sarrazin C; Manns MP; Pinto Marques Souza de Oliveira C; Sodeik B; Ciesek S; von Hahn T
PLoS One; 2015; 10(2):e0117152. PubMed ID: 25646622
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection.
Takemori T; Sugimoto-Ishige A; Nishitsuji H; Futamura Y; Harada M; Kimura-Someya T; Matsumoto T; Honma T; Tanaka M; Yaguchi M; Isono K; Koseki H; Osada H; Miki D; Saito T; Tanaka T; Fukami T; Goto T; Shirouzu M; Shimotohno K; Chayama K
J Virol; 2022 Mar; 96(5):e0168621. PubMed ID: 34985994
[TBL] [Abstract][Full Text] [Related]
18. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors.
Goh B; Choi J; Kang JA; Park SG; Seo J; Kim TY
J Pharm Biomed Anal; 2020 Jan; 178():112959. PubMed ID: 31722821
[TBL] [Abstract][Full Text] [Related]
19. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.
Yan H; Zhong G; Xu G; He W; Jing Z; Gao Z; Huang Y; Qi Y; Peng B; Wang H; Fu L; Song M; Chen P; Gao W; Ren B; Sun Y; Cai T; Feng X; Sui J; Li W
Elife; 2012 Nov; 1():e00049. PubMed ID: 23150796
[TBL] [Abstract][Full Text] [Related]
20. Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets.
Yu Y; Li S; Liang W
Emerg Microbes Infect; 2018 Jul; 7(1):134. PubMed ID: 30050063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]